Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.775 USD | -5.93% | -4.95% | -32.73% |
03:30pm | Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target | MT |
05-08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.73% | 89.01M | |
+17.97% | 123B | |
+14.77% | 107B | |
-4.51% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-12.21% | 16.23B | |
+2.50% | 13.43B | |
+24.80% | 11.32B |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Insider Trends: Insider Prolongs 90-Day Selling Trend at Relmada Therapeutics